Cellebrite DI (NASDAQ:CLBT - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at Needham & Company LLC in a report issued on Friday,Benzinga reports. They presently have a $24.00 target price on the stock. Needham & Company LLC's target price points to a potential upside of 44.40% from the stock's current price.
CLBT has been the subject of several other research reports. Lake Street Capital increased their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. JPMorgan Chase & Co. dropped their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $22.43.
Check Out Our Latest Stock Report on Cellebrite DI
Cellebrite DI Stock Up 0.5%
NASDAQ:CLBT traded up $0.09 during mid-day trading on Friday, hitting $16.62. 1,284,644 shares of the stock traded hands, compared to its average volume of 1,480,137. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of -11.96, a PEG ratio of 4.27 and a beta of 1.32. Cellebrite DI has a 52 week low of $10.55 and a 52 week high of $26.30. The firm's 50 day moving average is $18.36 and its two-hundred day moving average is $20.08.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The business had revenue of $107.55 million during the quarter, compared to analysts' expectations of $109.36 million. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The business's quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the company posted $0.08 earnings per share. As a group, research analysts predict that Cellebrite DI will post 0.3 EPS for the current year.
Institutional Investors Weigh In On Cellebrite DI
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bosun Asset Management LLC increased its position in shares of Cellebrite DI by 1.4% in the 4th quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock worth $954,000 after purchasing an additional 584 shares during the last quarter. OneDigital Investment Advisors LLC grew its position in shares of Cellebrite DI by 2.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock valued at $556,000 after buying an additional 688 shares during the last quarter. TD Waterhouse Canada Inc. grew its position in shares of Cellebrite DI by 1.8% during the 4th quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock valued at $1,046,000 after buying an additional 859 shares during the last quarter. Strategic Advisors LLC grew its position in shares of Cellebrite DI by 3.4% during the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company's stock valued at $641,000 after buying an additional 950 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its position in shares of Cellebrite DI by 24.7% during the 1st quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company's stock valued at $119,000 after buying an additional 1,214 shares during the last quarter. Institutional investors own 45.88% of the company's stock.
About Cellebrite DI
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
